// App-Quantinova.ai

4545 : Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).

Researchers

Presenter

  • Chelsea K. Osterman

Principal Investigators

  • Dilip Sankar Babu

  • Daniel M. Geynisman

  • Bianca Lewis

  • Robert A. Somer

  • Arjun Vasant Balar

  • Matthew R. Zibelman

  • Elizabeth A. Guancial

  • Gianna Antinori

  • Vivek Narayan

  • Thomas J. Guzzo

  • Elizabeth R. Plimack

  • David J. Vaughn

  • Chunkit Fung

  • Ronac Mamtani

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • University of Rochester Medcal Center, Rochester, NY

  • Fox Chase Cancer Center, Philadelphia, PA

  • Cooper Cancer Institute, Voorhees, NJ

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Fordham University, New York City, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved